

18 May 2026.

To,

BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001  
BSE Script Code: 531599

National Stock Exchange of India Ltd.  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E),  
Mumbai - 400 051  
NSE Symbol: FDC

**Sub: Intimation under Regulations 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') – ANDA approval for Cefixime for Oral Suspension USP, 100 mg/5 mL and 200 mg/ 5 mL.**

Dear Sir/Madam,

This is to inform you that, the Company has been granted **ANDA approval by United States Food and Drug Administration (U.S.FDA)**, for **Cefixime for Oral Suspension USP, 100 mg / 5 mL and 200 mg/ 5 mL**.

Kindly take the same on record.

Thanking you,

Yours truly,  
**For FDC LIMITED**

**Varsharani Katre**  
**Company Secretary & Legal Head**  
**Membership No. F-8948**